New CRISPR tool disrupts gene in leukemia cells

Myeloblasts with Auer rods seen in acute myeloid leukemia

CRISPR gene editing is a cutting-edge tool that is gaining more and more ground as a way to treat diseases. And as shown in a new study, researchers at the Wellcome Trust Sanger Institute have identified genes that could serve as targets to treat acute myeloid leukemia (AML).

Leukemia cells spread in bone marrow and can be very difficult to control. To create a new method for knocking the cells back, the team of scientists designed a CRISPR/Cas9 technique that would take out all of the genes in the cancer cell individually, eventually narrowing down the ones that would have the greatest effect.

One gene in particular, called KAT2A, when inhibited, disrupted the growth and survival of the leukemia cells without harming surrounding healthy ones. In tests on mice with human leukemia cells, the animals lived longer when KAT2A was disrupted.

Virtual Roundtable

ESMO Post Show: Highlights From the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields.

"This is an exciting finding, as KAT2A inhibition worked on a number of primary AML cells with diverse genotypes,” study co-author Konstantinos Tzelepis said in a release. “Whilst the gene needs to be studied in greater depth to understand its potential for use in the clinic, we show that targeting KAT2A destroyed AML cells in the laboratory while sparing healthy blood cells."

The research was funded in part by the Kay Kendall Leukaemia Fund. The results were published in Cell Reports.

"Previous studies showed proof of principle, but this is one of the first systematic attempts to identify the genetic vulnerabilities of AML,” said co-author Kosuke Yusa of the Sanger Institute. “We have improved and applied CRISPR-Cas 9 technology to look at what actually kills cells. CRISPR is becoming a powerful technique in cancer research because it overcomes some of the limitations of earlier tools."

Suggested Articles

Amunix reported that a single dose of its lead T-cell engager caused caused large HER2-positive tumors to shrink in mice.

A COVID drug made from an antibody fragment was effective in preventing and treating SARS-CoV-2 in rodent models and amenable to inhaled formulations.

An SHP2 inhibitor discovered at MD Anderson caused tumors to shrink in mouse models of drug-resistant, EGFR-mutated NSCLC.